References
- Savoie N , BoothBP, BradleyTet al. 2008 White paper: the 2nd Calibration and Validation Group Workshop on recent issues in good laboratory practice bioanalysis. Bioanalysis1(1), 19–30 (2009).
- US FDA. Guidance for Industry: Bioanalytical Method Validation (2001).
- Viswanathan CT , BansalS, BoothBet al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Workshop/Conference Report. AAPS J.9(1), E30–E42 (2007).
- Fast D , KelleyM, ViswanathanCTet al. Workshop report and follow-up: AAPS workshop on current topics in GLP bioanalysis; assay reproducibility for incurred samples – implications of Crystal City recommendations. AAPS J.11(2), 238–241 (2009).
- DeSilva B , SmithW, WeinerRet al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res.20, 1885–1900 (2003).
- Smolec J , DeSilvaB, SmithWet al. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm. Res.22(1), 1425–1431 (2005).
- European Medicines Agency. Guideline on Bioanalytical Method Validation (2011). www.ema.europa.eu/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf
- US FDA. Draft Guidance for Industry: Bioanalytical Method Validation (2013).
- US FDA. Guidance for Industry: Bioanalytical Method Validation (2018). www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf
- Findlay J , DillardR. Appropriate calibration curve fitting in ligand binding assays. AAPS J.9(2), E260–E267 (2007).
- Booth B , ArnoldME, DeSilvaBet al. Workshop report: Crystal City V – quantitative bioanalytical method validation and implementation: the 2013 Revised FDA Guidance. AAPS J.17(2), 277–288 (2015).
- Findlay J , SmithW, LeeJet al. Validation of immunoassays for bioanalysis a pharmaceutical industry perspective. J. Pharm. Biomed. Anal.21, 1249–1273 (2000).
- ANVISA. Resolution RDC 27 Minimum Requirements for Bioanalytical Method Validation Used in Studies with the Purpose of Registration and Post-registration of Medicines.Agencia National de Vigilancia Sanitaria, Brazil ( 2012).
- Japan, MHLW. Guideline on bioanalytical method validation in pharmaceutical development (2013). http://www.nihs.go.jp/drug/BMV/250711_BMV-GL.pdf
- Japan, MHLW. Guideline on bioanalytical method (ligand binding assay) validation in pharmaceutical development (2014). http://www.nihs.go.jp/drug/BMV/260530_LBA-GL_E.pdf.
- Compendium of papers from the Global Bioanalysis Consortium. http://www.globalbioanalysisconsortium.org/GBCPapers
- European Medicines Agency. Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples (2012). www.ema.europa.eu/en/documents/regulatory-procedural-guideline/reflection-paper-guidance-laboratories-perform-analysis-evaluation-clinical-trial-samples_en.pdf
- US FDA. Guidance for industry, immunogenicity testing of therapeutic protein products – developing and validating assays for anti-drug antibody detection (2019). www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm629728.pdf
- Casadevall N , NatafJ, VironBet al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med.346, 469–475 (2002).
- Li J , YangC, XiaYet al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood98, 3241–3248 (2001).
- Chung CH , MirakhurB, ChanEet al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med.358, 1109–1117 (2008).
- European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on immunogenicity assessment of therapeutic proteins (2017). www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf
- Piccoli SP . The FDA/C-path/Duke–Margolis public workshop on analytical validation of assays for biomarker qualification: an update. Bioanalysis10(12), 893–896 (2018).
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) M10 Concept Paper. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M10/ICH_M10_Concept_paper_final_7Oct2016.pdf